PTS Pulse

0
by in

PTS Diagnostics Unveils New Capillary Tube

PTS Diagnostics Unveils New Capillary Tube

Advanced blood collection technology combines speed, efficiency and savings

Indianapolis – January 21, 2015 – PTS Diagnostics, the U.S.-based manufacturer of both the CardioChek® brand and the A1CNow® family of point-of-care diagnostic products, today announced that it has launched a line of capillary tubes using a new and innovative technology. The PTS Diagnostics Capillary Tubes, which provide speed, efficiency and savings — especially for applications where exact sample volumes are required — are now available from PTS Diagnostics’ distributors around the world.

PTS Diagnostics Capillary Tubes provide better efficiency and are designed to be easier to use than traditional blood transfer tubes. Using a single glass tube with plastic casing, the PTS Diagnostics Capillary Tubes provide consistent selfwicking technology to deliver preset volumes. This improved design is perfect for blood collection needs addressing a wide range of applications across many different medical devices. In addition, the new PTS Diagnostics Capillary Tubes provide significant savings over traditional pipettes with the same or better quality.

These new PTS Diagnostics Capillary Tubes can increase efficiency in workflow by providing: 

  • Ease-of-use with no assembly
  • One-hand blood collection and dosing
  • A glass tube to ensure easy blood collection
  • Bulb-squeeze dispensing technology that ensures consistent performance
  • Only one item to inventory (no plunger)

    • “In the health screening, workplace health and physician office environments, this new design provides many advantages over traditional blood transfer tubes,” said Robert Huffstodt, President and CEO of PTS Diagnostics. “PTS Diagnostics Capillary Tubes are ideal for low volume blood collection given the product’s one-hand operation, no assembly and precise self-wicking collection to preset volumes. This new technology combines speed, efficiency and savings.”

    These new capillary tubes are designed to be easy-to-use and require little additional training.

    “PTS Diagnostics is known for its lipid testing and A1C monitoring devices, however this new product will help us expand our reach across point-of-care testing as the new capillary tubes provide savings and efficiency across many tests including ABO/Rh Blood, IgE, HIV, hepatitis and various other infectious diseases to name a few,” said Huffstodt.

    PTS Diagnostics’ handheld, highly-accurate, fast, and economical diagnostic devices empower the medical community to quickly measure HbA1c and glucose, and generate a lipid (cholesterol) profile, all at the point of care.

    PTS Diagnostics’ portfolio includes the following systems:

  • CardioChek professional analyzers address the connection between heart attack, stroke, and diabetes by providing on-site lipid panel (total cholesterol, HDL cholesterol, and triglycerides) screening results in as little as 90 seconds and can also measure glucose. CardioChek professional analyzers calculate LDL cholesterol, the TC/HDL ratio, the LDL/HDL ratio, and non-HDL cholesterol.
  • The A1CNow+ system provides healthcare professionals with a fast, easy, and accurate method of obtaining HbA1c results while the patient is in the exam room. In just five minutes, clinicians have information to provide an immediate consultation with a patient. The A1CNow+ system is critical to diabetes management and is fully reimbursable.

    • About PTS Diagnostics – PTS Diagnostics is a global provider of point-of-care diagnostic products to the healthcare industry. Headquartered in Indianapolis, Indiana, PTS Diagnostics designs, manufactures, and markets products for distribution in over 120 countries around the world. The company has sales offices in Europe, Latin America, and the Pacific Rim. PTS Diagnostics’ products include both the CardioChek systems and A1CNow systems.

    All trademarks used or mentioned in this release are protected by law.

    For more information, visit www.ptsdiagnostics.com or contact Tom Wiser at +1-317-870-5610.

    MKG001159 Rev. 0 1/15
    0
    by in

    PTS Diagnostics Announces 14 New US and International Patents

    PTS Diagnostics Announces 14 New US and International Patents

    Proprietary technologies drive innovation in point-of-care testing

    Indianapolis – Feb. 25, 2015 – PTS Diagnostics, the U.S.-based manufacturer of both the CardioChek® brand and the A1CNow® family of point-of-care diagnostic products, has been granted 4 new U.S. patents and 10 new patents from Canada, Europe, Germany, India, Korea, and Mexico in just the last 18 months. Since mid-2013, PTS Diagnostics was awarded 5 patents related to its CardioChek test strips, 8 for its A1CNow+ system and one for a new test strip that can test multiple blood chemistries at the same time.

    “We continue to develop new and alternative innovations for our CardioChek test strip technology in the US and continue to be granted patents around the globe as we expand distribution of our A1CNow+ system to additional countries,” said Robert Huffstodt, President and CEO of PTS Diagnostics. “This technology ensures we deliver accurate and precise lipid, glucose and A1C testing and monitoring.”

    In approximately the last 18 months, PTS Diagnostics was granted these new patents:

  • United States: #8,460,539; #8,465,696; #8,642,320; #8,865,089
  • Canada: #2,654,292
  • Europe: #1 474 692; #1 725 650; #2 221 621
  • Germany: #112,012,000,32
  • Korea: #10-1,324,375, #10-1,347,472
  • India: #258,142; #257,235
  • Mexico: #315,864

    • PTS Diagnostics currently holds 91 U.S. and international patents and has 86 pending patent applications.

    “As we look to the future, we are anticipating the needs of our customers and are working diligently to create next-generation technology to expand the testing and services we provide,” said Huffstodt. “These new patents, combined with our pending applications, will fuel PTS Diagnostics’ growth in the future. We continue to have a robust pipeline of new innovation and look forward to the next year and beyond.”

    PTS Diagnostics’ products are sold in more than 120 countries and its CardioChek analyzers have screened more than 120 million people worldwide. In addition, sales of its A1CNow System surpassed 1 million tests in just 8 months after the company began manufacturing the A1C monitoring device.

    PTS Diagnostics’ handheld, highly-accurate, fast, and economical diagnostic devices empower the medical community to quickly measure HbA1c and glucose, and generate a lipid (cholesterol) profile, all at the point of care.

    PTS Diagnostics’ portfolio includes the following systems:

  •  CardioChek professional analyzers address the connection between heart attack, stroke, and diabetes by providing on-site lipid panel (total cholesterol, HDL cholesterol, and triglycerides) screening results in as little as 90 seconds and can also measure glucose. CardioChek professional analyzers calculate LDL cholesterol, the TC/HDL ratio, the LDL/HDL ratio, and non-HDL cholesterol.
  •  The A1CNow+ system provides healthcare professionals with a fast, easy, and accurate method of obtaining HbA1c results while the patient is in the exam room. In just five minutes, clinicians have information to provide an immediate consultation with a patient. The A1CNow+ system is critical to diabetes management and is fully reimbursable.

    • About PTS Diagnostics – PTS Diagnostics is a global provider of point-of-care diagnostic products to the healthcare industry. Headquartered in Indianapolis, Indiana, PTS Diagnostics designs, manufactures, and markets products for distribution in over 120 countries around the world. The company has sales offices in Europe, Latin America, and the Pacific Rim. PTS Diagnostics’ products include both the CardioChek systems and A1CNow systems.

    All trademarks used or mentioned in this release are protected by law.

    For more information, visit www.ptsdiagnostics.com or contact Tom Wiser at +1-317-870-5610.

    MKG001306 Rev. 0 2/15
    0
    by in

    PTS Diagnostics Introduces Secure Cloud-Based Solution Enhancing Corporate Wellness Programs and Improving Health Screeners' Productivity

    PTS Diagnostics Introduces Secure Cloud-Based Solution Enhancing Corporate Wellness Programs and Improving Health Screeners’ Productivity

    PTS Connect™ Wellness Solution is an online tool that digitizes data from screening events and promotes employee engagement in corporate wellness programs

    Indianapolis, March 10, 2015 – PTS Diagnostics, the U.S.-based manufacturer of both the CardioChek® brand and the A1CNow® family of point-of-care diagnostic products, announces the launch of the PTS Connect™ Wellness Solution. This secure cloud-based solution will empower health screening companies to screen more individuals faster and corporate wellness programs to improve outcomes by encouraging participants to monitor and track activity and progress online. In addition, it enables population health management by targeting wellness communication and aggregating data for at-risk individuals.

    In short, the PTS Connect Wellness Solution provides an opportunity to improve productivity, participant engagement and data analysis among organizations that manage wellness screenings and wellness programs.

    “The PTS Connect Wellness Solution is the complete Population Health Management tool. As a software solution for screening and wellness programs, the new online tool meets the needs of customers with a variety of goals,” said Robert Huffstodt, President and CEO of PTS Diagnostics. “Some customers may simply want to automate the acquisition of biometric results, provide immediate screening reports to participants
    and aggregate data. Others may want to grant online access to participants after the screening event, providing online education and enabling targeted wellness messaging. This flexible solution allows customers to grow their wellness platform over time to meet changing needs.”

    For health screeners, the software is capable of automated upload of biometric information from a CardioChek lipid and glucose analyzer, and from a weight scale, blood pressure monitor and pedometer. The biometric data is stored securely and can be synced instantaneously with a participant’s online wellness account.

    For corporate wellness programs, PTS Connect Wellness Solution offers a turnkey range of online tools and resources supporting healthy lifestyle change. PTS Connect offers a personal health assessment that produces wellness education based on individual needs. In addition, users can track and monitor physical activity over time. Educational offerings include quizzes, calculators, self-assessments and decision guides.

    “Our new platform was designed for screeners and corporate wellness programs,” said Huffstodt. “We have taken the entire health management continuum and created an online software solution to make screening and running a corporate wellness program easy. We are excited to begin offering these solutions via our global distribution network.”

    In addition to PTS Connect Wellness Solution, PTS Diagnostics’ portfolio includes the following systems:

  • CardioChek professional analyzers address the connection between heart attack, stroke, and diabetes by providing on-site lipid panel (total cholesterol, HDL cholesterol, and triglycerides) screening results in as little as 90 seconds and can also measure glucose. CardioChek professional analyzers calculate LDL cholesterol, the TC/HDL ratio, the LDL/HDL ratio, and non-HDL cholesterol.
  • The A1CNow+ system provides healthcare professionals with a fast, easy, and accurate method of obtaining HbA1c results while the patient is in the exam room. In just five minutes, clinicians have information to provide an immediate consultation with a patient. The A1CNow+ system is critical to diabetes management and is fully reimbursable.

    • About PTS Diagnostics – PTS Diagnostics is a global provider of point-of-care diagnostic products to the healthcare industry. Headquartered in Indianapolis, Indiana, PTS Diagnostics designs, manufactures, and markets products for distribution in over 120 countries around the world. The company has sales offices in Europe, Latin America, and the Pacific Rim. PTS Diagnostics’ products include both the CardioChek systems
    and A1CNow systems.

    All trademarks used or mentioned in this release are protected by law.

    For more information, visit www.ptsdiagnostics.com or contact Tom Wiser at +1-317-870-5610.

    MKG001343 Rev. 0 3/15
    0
    by in

    PTS Diagnostics Named to Inc. Magazine's 2015 List of the 5,000 Fastest Growing Private Companies

    PTS Diagnostics Named to Inc. Magazine’s 2015 List of the 5,000 Fastest Growing Private Companies

    Global medical device manufacturer selected for fifth time to prestigious list based on three-year sales growth of 137%

    Indianapolis, IN – August 17, 2015 – PTS Diagnostics, the U.S.-based manufacturer of both the CardioChek® brand and the A1CNow® family of point-of-care diagnostic products, was ranked as one of the nation’s fastest-growing private companies by Inc. magazine. The magazine’s 34th annual “Inc. 5000 list” ranked PTS Diagnostics as the 2,684th fastest growing company in the United States.

    Last year, PTS Diagnostics earned its place on the list with 80 percent growth over the previous three years. PTS Diagnostics continued to increase sales by earning 137 percent growth over the past three years in the 2015 list.

    “Our fast, easy, portable and accurate point-of-care diagnostic devices test people around the world for multiple key disease states, including high cholesterol and diabetes, with just a simple fingerstick,” said Robert Huffstodt, President and CEO of PTS Diagnostics. “We have also just expanded our portfolio of products to include the PTS Detect tobacco-detection system, the only point-of-care device that offers quantitative results from a fingerstick.”

    In addition, the company recently launched the PTS Pod collection system further innovating its line of point-of-care testing options. To complement its line of diagnostic devices, in early 2015 the company introduced PTS Diagnostics™ capillary tubes, and the PTS Connect™ wellness solution, an online information management and patient communication software tool.

    Founded in 1992, PTS Diagnostics was specially recognized by Inc. Magazine as a Five-Time Inc. 5000 Honoree. The company earned its spot on the list with rankings in 2007, 2008, 2013, 2014 and now 2015.

    “As we continue to grow our business in the US and around the globe, we are pleased that our devices will test upwards of 25 million people this year,” said Huffstodt. “Our nearly 180 employees work hard to continue our ongoing commitment to provide a full suite of world-class point-of-care diagnostic solutions to healthcare professionals of all kinds, all around the world.”

    The Inc. 5000 profiles are available on http://www.inc.com.

    “The story of this year’s Inc. 5000 is the story of great leadership. In an incredibly competitive business landscape, it takes something extraordinary to take your company to the top,” said Inc. President and Editor-In-Chief Eric Schurenberg.

    Huffstodt concluded, “It’s gratifying for all of us to see our growth strategies validated in the marketplace and recognized by the media. Our goal is for a repeat performance in 2016.”

    About PTS Diagnostics
    PTS Diagnostics is an innovative point-of-care diagnostics solutions provider that partners with patients and healthcare professionals to provide the right information at the right time to make the right decisions. The company’s name represents the three pillars upon which it has built its long-term success: People, Technology and Service.

    PTS Diagnostics’ signature products include the CardioChek® lipid analyzer and the A1CNow® family of products. The CardioChek® family of products have screened more than 120 million patients worldwide while the A1CNow® product line works to enable people to lead healthier lives through ongoing management of diabetes. Together these products help identify individuals with cardiometabolic syndrome, a cluster of conditions that increase risks of developing cardiovascular disease or diabetes.

    Headquartered in Indianapolis, Indiana, PTS Diagnostics designs, manufactures, distributes and markets products for distribution in more than 135 countries around the world. More information is available at www.ptsdiagnostics.com .

    For more information, visit www.ptsdiagnostics.com or contact Tom Wiser at 317-870-5610.

    SOURCE: PTS Diagnostics

    MKG001660 Rev. 0 8/15
    0
    by in

    PTS Diagnostics will Present at the American Diabetes Association's (ADA) 76th Scientific Sessions

    PTS Diagnostics will Present at the American Diabetes Association’s (ADA) 76th Scientific Sessions

    Manufacturer of A1CNow+® will exhibit and present a poster at the world’s largest meeting on diabetes June 10-14 in New Orleans

    Indianapolis – June 9, 2016 – PTS Diagnostics, the U.S.-based manufacturer of point-of-care blood testing devices, including the CardioChek® and A1CNow® systems, will exhibit and participate in the poster sessions at the American Diabetes Association’s (ADA) 76th Scientific Sessions held in New Orleans.

    PTS Diagnostics and eTrueNorth’s poster titled “Failure of Fasting Blood Glucose Screening to Detect All Persons with Diabetes or Prediabetes” will be on display in the “Clinical Therapeutics/New Technology–Glucose Monitoring and Sensing” area in the Poster Hall on June 11 to June 13. James Anderson, MD, lead author of the presentation and PTS Diagnostics’ medical director, will be available to discuss his research on Sunday, June 12, from noon to 2:00 p.m. at the poster’s location, 864-P.

    Further, Dr. Anderson will participate in a moderated poster discussion in the session titled “The Role of Glucose Testing and Variability” on Monday, June 13 from 1 to 2:00 p.m.

    Attendees to the ADA Scientific Sessions can visit PTS Diagnostics in Booth #117 during the show.

    “PTS Diagnostics is pleased to be contributing to the body of knowledge that strives to screen, diagnose, treat and manage diabetes,” said Dr. Anderson. “At PTS Diagnostics, our focus is to provide healthcare professionals an easy, fast and accurate way to measure A1C. Our presentation focuses on the importance of A1C screening and testing for at-risk individuals.”

    At the conclusion of the ADA event (June 14), this poster presentation will be available at www.a1cnow.com.

    PTS Diagnostics manufactures A1CNow+® system, a fast and easy way of obtaining accurate A1C results with just a fingerstick in just 5 minutes at the point of care. The portable, small medical device can easily be used in multiple exam rooms, is CLIAwaived, FDA-cleared and is NGSP certified. This innovative technology enables healthcare professional to communicate face-to-face with patients about their diabetes control in minutes, not days.

    About PTS Diagnostics
    PTS Diagnostics is an innovative global point-of-care diagnostics solutions provider that partners with patients and healthcare professionals to provide the right information at the right time to make the right decisions. The company’s name represents the three pillars upon which it has built its long-term success: People, Technology and Service. Headquartered in Indianapolis, Indiana, PTS Diagnostics designs, manufactures, distributes and markets products for distribution in more than 135 countries around the world. For more information, visit www.ptsdiagnostics.com or contact Tom Wiser at 317- 870-5610 or twiser@ptsdiagnostics.com.

    MKG001963 Rev. 0 6/16